Patent Ductus Arteriosus (PDA)
0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Merit MedicalBloom Micro Occluder System
PFM MedicalPDA Coil
AbbottDevice closure with AMPLATZER Duct Occluder
Clinical Trials (3)
Total enrollment: 675 patients across 3 trials
PREEMIE: Study for Treatment of PDA in Premature Infants
Start: Mar 2025Est. completion: Mar 202955 patients
N/AActive Not Recruiting
Nit-Occlud PDA Post-Approval Study
Start: Aug 2014Est. completion: Aug 2022184 patients
N/ACompleted
Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
Start: Oct 1999Est. completion: Feb 2009436 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.